Use of triazoles for the treatment of invasive aspergillosis: A three‐year cohort analysis. Issue 1 (30th October 2019) - Cheng, Matthew P.
Summary: In a 3‐year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.